Literature DB >> 6353231

Does drug therapy slow radiographic deterioration in rheumatoid arthritis?

L Iannuzzi, N Dawson, N Zein, I Kushner.   

Abstract

Many clinicians believe that slow-acting therapeutic agents, such as fold, penicillamine, the antimalarials, and cytotoxic drugs, can retard joint destruction in rheumatoid arthritis. We reviewed 60 published studies employing these drugs to evaluate critically the evidence that drug therapy can slow the radiographic progression of disease. Seventeen studies were found that included radiographic assessment of both treated and control groups; they were analyzed using methodologic criteria known to be important in affecting the results of drug trials. In addition to numerous qualitative methodologic deficiencies, many studies showed inadequacies in sample size and duration of treatment, and the drug dosage used varied from one study to another. We found evidence suggesting that both gold and cyclophosphamide can retard radiographic progression of joint destruction. At present, there are too few technically adequate studies to permit even provisional conclusions concerning other agents.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6353231     DOI: 10.1056/NEJM198310273091704

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  34 in total

Review 1.  Osteoporosis: whose problem is it?

Authors:  A D Woolf
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

2.  In rheumatoid arthritis is compliance in physicians more of a problem than compliance in patients?

Authors:  R J Rooney; W W Buchanan
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

Review 3.  Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis.

Authors:  H A Capell; M Brzeski
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

4.  "Second line" drugs for rheumatoid arthritis.

Authors:  R D Sturrock
Journal:  BMJ       Date:  1991-07-27

Review 5.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

6.  Rheumatoid inflammation and joint destruction: cause and effect or parallel phenomena?

Authors:  J D Williams; D L Scott; F B DeBrito; D A Willoughby; E C Huskisson
Journal:  Agents Actions       Date:  1986-08

7.  Randomized trial of switching rheumatoid arthritis patients in remission with injectable gold to auranofin.

Authors:  P E Prete; J Zane; M Krailo; M Bulanowski
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

8.  Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study.

Authors:  A W van Rijthoven; B A Dijkmans; H S Goei The; J Hermans; Z L Montnor-Beckers; P C Jacobs; A Cats
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

9.  Prediction of progressive joint damage in patients with rheumatoid arthritis receiving gold or D-penicillamine therapy.

Authors:  P T Dawes; P D Fowler; R Jackson; M Collins; M F Shadforth; R Stone; D L Scott
Journal:  Ann Rheum Dis       Date:  1986-11       Impact factor: 19.103

10.  A modified mouse air pouch model for evaluating the effects of compounds on granuloma induced cartilage degradation.

Authors:  K M Bottomley; R J Griffiths; T J Rising; A Steward
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.